<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000726</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 015</org_study_id>
    <secondary_id>FDA 20D</secondary_id>
    <secondary_id>10991</secondary_id>
    <nct_id>NCT00000726</nct_id>
  </id_info>
  <brief_title>Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome</brief_title>
  <official_title>Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To explore the safety and usefulness of foscarnet, an antiviral agent, in the treatment of&#xD;
      cytomegalovirus (CMV) retinitis. Untreated CMV retinitis is a rapidly progressive, blinding&#xD;
      disease in AIDS patients. The manner in which foscarnet breaks down in the body and the&#xD;
      effect of increasing periodic intravenous doses are also studied. Foscarnet is active in&#xD;
      vitro (test tube) against herpes viruses, including CMV, by inhibiting the virus DNA&#xD;
      polymerases, enzymes necessary for virus replication, without affecting cellular DNA&#xD;
      polymerases. Opportunistic CMV disease in AIDS is usually seen as retinitis, colitis,&#xD;
      esophagitis, hepatitis, pancreatitis, encephalitis, or pneumonia. Ganciclovir has been used&#xD;
      to treat AIDS patients with CMV disease but can cause severe neutropenia (very low neutrophil&#xD;
      cell counts). Foscarnet does not suppress the production of neutrophils or other leukocytes&#xD;
      (myelosuppression) and has shown in vitro activity against HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Foscarnet is active in vitro (test tube) against herpes viruses, including CMV, by inhibiting&#xD;
      the virus DNA polymerases, enzymes necessary for virus replication, without affecting&#xD;
      cellular DNA polymerases. Opportunistic CMV disease in AIDS is usually seen as retinitis,&#xD;
      colitis, esophagitis, hepatitis, pancreatitis, encephalitis, or pneumonia. Ganciclovir has&#xD;
      been used to treat AIDS patients with CMV disease but can cause severe neutropenia (very low&#xD;
      neutrophil cell counts). Foscarnet does not suppress the production of neutrophils or other&#xD;
      leukocytes (myelosuppression) and has shown in vitro activity against HIV.&#xD;
&#xD;
      Treatment is given for a total of 10 weeks with a 2-week induction regimen followed by&#xD;
      randomization to daily maintenance foscarnet for 8 weeks. If induction therapy is tolerated&#xD;
      without unexpected toxicity, patients are allowed to self-administer foscarnet at home via&#xD;
      central venous catheter and may receive up to 11 days of induction therapy by&#xD;
      self-administration on an outpatient basis. Foscarnet will be administered in open-label&#xD;
      fashion so that both investigator and patient will know the dose. Within the study, there are&#xD;
      8 patients who upon entering the 2nd week of maintenance foscarnet therapy are treated with&#xD;
      zidovudine (AZT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1992</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>53</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Any potentially nephrotoxic agent, especially aminoglycosides, pentamidine, or&#xD;
             amphotericin B.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Excluded within 7 days of study entry:&#xD;
&#xD;
          -  Any potentially nephrotoxic agent.&#xD;
&#xD;
          -  Excluded within 14 days of study entry:&#xD;
&#xD;
          -  Cytomegalovirus hyperimmune globulin in therapeutic doses.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Investigational agents.&#xD;
&#xD;
          -  Amphotericin B maintenance for a systemic mycosis.&#xD;
&#xD;
        Known allergy to foscarnet.&#xD;
&#xD;
        Active AIDS-defining opportunistic infection other than cytomegalovirus (CMV) including&#xD;
        systemic mycosis, pulmonary or neurologic impairment (comatose).&#xD;
&#xD;
        Patient must be diagnosed as having:&#xD;
&#xD;
          -  AIDS CDC Group IV.C.&#xD;
&#xD;
          -  Cytomegalovirus (CMV) retinitis as identified by its characteristic ophthalmoscopic&#xD;
             appearance and verified by fundus photography.&#xD;
&#xD;
          -  One pending culture for CMV from blood and urine prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobson M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC School of Medicine / Norris Cancer Hosp</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobson MA, Polsky B, Causey D, Davis R, Tong W, O'Donnell JJ, Kuppermann BD, Heinemann MH, Feinberg J, Lizak P, et al. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. Antimicrob Agents Chemother. 1994 May;38(5):1190-3. doi: 10.1128/AAC.38.5.1190.</citation>
    <PMID>8067763</PMID>
  </reference>
  <reference>
    <citation>Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May;33(5):742-5. doi: 10.1128/AAC.33.5.742.</citation>
    <PMID>2546491</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May;33(5):736-41. doi: 10.1128/AAC.33.5.736.</citation>
    <PMID>2546490</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct;158(4):862-5. No abstract available.</citation>
    <PMID>2844921</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, O'Donnell JJ, Kuppermann BD, Heinemann MH, Holland GN, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993 Aug;168(2):444-8. doi: 10.1093/infdis/168.2.444.</citation>
    <PMID>8393058</PMID>
  </reference>
  <reference>
    <citation>Jacobson MA, Causey D, Hardy D, Polsky B, Mills J, Feinberg JE. Tolerance and efficacy of daily intravenous (IV) maintenance foscarnet (PFA) therapy for cytomegalovirus (CMV) retinitis in AIDS patients (ACTG protocol 015). Int Conf AIDS. 1989 Jun 4-9;5:242 (abstract no MBP123)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Foscarnet</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

